Last reviewed · How we verify
6R BH4
At a glance
| Generic name | 6R BH4 |
|---|---|
| Also known as | Tetrahydrobiopterin |
| Sponsor | University of Michigan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of BH4 Responsiveness in Our PKU Patients (PHASE1)
- : Vascular Function in Health and Disease (PHASE1)
- Exercise and NO in HFrEF (EARLY_PHASE1)
- Novel Approaches for Improving Vascular Function in Veterans With HFpEF (PHASE1)
- Study of Kuvan Treatment in Adults With GTPCH Deficiency (PHASE1, PHASE2)
- Neurovascular Transduction During Exercise in Chronic Kidney Disease (PHASE2)
- Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease (PHASE4)
- O2 Transport and Utilization in Health and Lung Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6R BH4 CI brief — competitive landscape report
- 6R BH4 updates RSS · CI watch RSS
- University of Michigan portfolio CI